Flexion Therapeutics Target of Unusually Large Options Trading (FLXN)

Flexion Therapeutics (NASDAQ:FLXN) saw unusually large options trading activity on Wednesday. Traders acquired 1,551 call options on the stock. This is an increase of approximately 1,084% compared to the typical volume of 131 call options.

Shares of Flexion Therapeutics stock opened at $24.72 on Thursday. The company has a debt-to-equity ratio of 0.58, a current ratio of 13.02 and a quick ratio of 12.96. Flexion Therapeutics has a fifty-two week low of $16.51 and a fifty-two week high of $32.25.

Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings results on Thursday, March 8th. The specialty pharmaceutical company reported ($1.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.27). The company had revenue of $0.36 million for the quarter, compared to analyst estimates of $1.29 million. equities analysts predict that Flexion Therapeutics will post -5.18 EPS for the current fiscal year.



Several analysts have recently weighed in on the stock. BidaskClub lowered shares of Flexion Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, January 20th. Zacks Investment Research raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. Wells Fargo set a $39.00 price target on shares of Flexion Therapeutics and gave the company a “buy” rating in a report on Tuesday, April 3rd. ValuEngine raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 5th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price target (down previously from $37.00) on shares of Flexion Therapeutics in a report on Friday, March 9th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $99.00.

Institutional investors have recently modified their holdings of the stock. Schroder Investment Management Group increased its holdings in shares of Flexion Therapeutics by 21.0% in the fourth quarter. Schroder Investment Management Group now owns 516,981 shares of the specialty pharmaceutical company’s stock valued at $12,945,000 after purchasing an additional 89,806 shares in the last quarter. Virginia Retirement Systems ET AL acquired a new stake in Flexion Therapeutics during the 3rd quarter worth $496,000. American Financial Group Inc. acquired a new stake in Flexion Therapeutics during the 4th quarter worth $5,280,000. Eaton Vance Management grew its holdings in Flexion Therapeutics by 37.2% during the 4th quarter. Eaton Vance Management now owns 12,900 shares of the specialty pharmaceutical company’s stock worth $323,000 after acquiring an additional 3,500 shares during the period. Finally, Perceptive Advisors LLC acquired a new stake in Flexion Therapeutics during the 4th quarter worth $7,712,000. 94.46% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was reported by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://dakotafinancialnews.com/2018/04/12/flexion-therapeutics-target-of-unusually-large-options-trading-flxn.html.

About Flexion Therapeutics

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply